Market Cap 69.24M
Revenue (ttm) 17.59M
Net Income (ttm) -21.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -123.31%
Debt to Equity Ratio 0.00
Volume 127,000
Avg Vol 362,020
Day's Range N/A - N/A
Shares Out 46.16M
Stochastic %K 13%
Beta 0.79
Analysts Strong Sell
Price Target $4.33

Company Profile

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed it...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 620 4187
Address:
Industrious 823 Congress Ave, Suite 300, Austin, United States
TurningAProfit
TurningAProfit Jun. 24 at 1:48 PM
0 · Reply
NyseDayTrader
NyseDayTrader Jun. 24 at 12:41 PM
$HYFT $HYFT Interesting to see some of the early conversations coming out of BIO. The discussion isn't "Who has the biggest AI model?" It's becoming: Who has the best biological context? One comment asked whether pharma would eventually move away from generic AI models and toward biology-specific architectures. The response: "It's already happening 😊" Maybe that's why we're hearing more about ReefIQ, LensAI, biological context, recurring enterprise contracts, and real-world validation. The market may still be trying to figure out what MindWalk is. The people having these conversations don't seem nearly as confused.
0 · Reply
NyseDayTrader
NyseDayTrader Jun. 24 at 11:03 AM
$HYFT TenGildong🏴‍☠️ @Ten_Gildong Translated from Korean $HYFT Mindwalk technology introduction post에 의견을 남긴 디지털헬스 전략가인 Kat Usop Ricardo, this is a complete game changer in the TechBio field! I'm truly proud to see you breaking down these massive milestones one by one. The approach of anchoring computational reasoning to evolutionary biology, rather than relying on mere standard statistical correlations, is an absolutely brilliant way to tackle the hallucination issues in novel drug development. Moreover, the fact that this approach has already produced validated results in a preclinical dengue program demonstrates that your investment/technology thesis is spot on. Now that the platform has successfully secured its first recurring revenue enterprise contract, do you think this shift to an 'evolution-based' approach will ultimately pressure incumbent big pharma companies to abandon general-purpose foundation models and adopt biology-specific architectures?
0 · Reply
RussMe
RussMe Jun. 24 at 1:47 AM
0 · Reply
Uncle_Salty
Uncle_Salty Jun. 23 at 3:19 PM
$HYFT The endless waiting is
0 · Reply
Tester87100
Tester87100 Jun. 23 at 1:47 PM
0 · Reply
StockingGecks
StockingGecks Jun. 23 at 1:47 AM
0 · Reply
Bigcountry8
Bigcountry8 Jun. 22 at 11:23 PM
$HYFT https://www.foxnews.com/opinion/robert-f-kennedy-jr-future-medicine-built-america
0 · Reply
chucky1110
chucky1110 Jun. 22 at 5:44 PM
$HYFT Bubbles ain't like Keir Starmer - she won't resign willingly! AGM voting is approaching fast! What are you all going to do? Remember, that not bothering to vote = automatic vote for Bubbles! She knows that and that's how she stays in power. I did my research on Ai!
1 · Reply
Right80
Right80 Jun. 22 at 3:50 PM
$HYFT These guys just can't get into the conversation. 10% of the ABSI and ABCL volumes, talking about Dengue for over a year. Let's go already!!
0 · Reply
Latest News on HYFT
MindWalk launches ReefIQ context layer

2026-06-10T13:25:28.000Z - 14 days ago

MindWalk launches ReefIQ context layer


MindWalk announces launch of Pandemic Response Platform

2026-05-27T14:28:47.000Z - 4 weeks ago

MindWalk announces launch of Pandemic Response Platform


The Biology Came First.

May 18, 2026, 8:34 AM EDT - 5 weeks ago

The Biology Came First.


MindWalk initiated with a Buy at JonesResearch

2026-04-15T20:18:56.000Z - 2 months ago

MindWalk initiated with a Buy at JonesResearch


MindWalk Holdings Earnings Call Transcript: Q3 2026

Mar 12, 2026, 10:30 AM EDT - 3 months ago

MindWalk Holdings Earnings Call Transcript: Q3 2026


MindWalk Holdings Earnings release: Q3 2026

Mar 12, 2026, 10:30 AM EDT - 3 months ago

MindWalk Holdings Earnings release: Q3 2026


MindWalk Holdings Slides: Q3 2026

Mar 12, 2026, 10:30 AM EDT - 3 months ago

MindWalk Holdings Slides: Q3 2026


MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

Mar 12, 2026, 8:31 AM EDT - 3 months ago

MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results


MindWalk announces nanobody discovery platform

2026-03-06T21:05:43.000Z - 3 months ago

MindWalk announces nanobody discovery platform


MindWalk announces advance in influenza program

2026-01-11T19:45:16.000Z - 5 months ago

MindWalk announces advance in influenza program


MindWalk Holdings Earnings Call Transcript: Q2 2026

Dec 15, 2025, 10:30 AM EST - 6 months ago

MindWalk Holdings Earnings Call Transcript: Q2 2026


MindWalk Holdings Earnings release: Q2 2026

Dec 15, 2025, 10:30 AM EST - 6 months ago

MindWalk Holdings Earnings release: Q2 2026


MindWalk Holdings Slides: Q2 2026

Dec 15, 2025, 10:30 AM EST - 6 months ago

MindWalk Holdings Slides: Q2 2026


MindWalk appoints R. Scott Areglado as Chief Financial Officer

2025-10-21T13:10:11.000Z - 8 months ago

MindWalk appoints R. Scott Areglado as Chief Financial Officer


MindWalk appoints Thomas Lynch as chief business officer

2025-10-15T11:05:12.000Z - 9 months ago

MindWalk appoints Thomas Lynch as chief business officer


MindWalk announces up to 2.3M share stock repurchase program

2025-10-09T11:05:22.000Z - 9 months ago

MindWalk announces up to 2.3M share stock repurchase program


MindWalk Announces Share Repurchase Program

Oct 9, 2025, 7:00 AM EDT - 9 months ago

MindWalk Announces Share Repurchase Program


MindWalk advances AI-designed GLP-1 therapeutics program

2025-09-22T11:25:07.000Z - 9 months ago

MindWalk advances AI-designed GLP-1 therapeutics program


MindWalk Holdings Earnings Call Transcript: Q1 2026

Sep 15, 2025, 10:30 AM EDT - 10 months ago

MindWalk Holdings Earnings Call Transcript: Q1 2026


MindWalk Holdings Earnings release: Q1 2026

Sep 15, 2025, 10:30 AM EDT - 10 months ago

MindWalk Holdings Earnings release: Q1 2026


MindWalk Holdings Earnings Call Transcript: Q4 2025

Jul 29, 2025, 10:30 AM EDT - 11 months ago

MindWalk Holdings Earnings Call Transcript: Q4 2025


MindWalk Holdings Earnings release: Q4 2025

Jul 29, 2025, 10:30 AM EDT - 11 months ago

MindWalk Holdings Earnings release: Q4 2025


MindWalk Holdings Annual report: Q4 2025

Jul 29, 2025, 10:30 AM EDT - 11 months ago

MindWalk Holdings Annual report: Q4 2025


MindWalk Holdings Earnings Call Transcript: Q3 2025

Mar 28, 2025, 10:30 AM EDT - 1 year ago

MindWalk Holdings Earnings Call Transcript: Q3 2025


MindWalk Holdings Earnings release: Q3 2025

Mar 28, 2025, 10:30 AM EDT - 1 year ago

MindWalk Holdings Earnings release: Q3 2025


ImmunoPrecise Antibodies Announces Key Leadership Changes

Feb 24, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Announces Key Leadership Changes


IPA Announces Resignation of Chief Financial Officer

Dec 31, 2024, 7:56 PM EST - 1 year ago

IPA Announces Resignation of Chief Financial Officer


TurningAProfit
TurningAProfit Jun. 24 at 1:48 PM
0 · Reply
NyseDayTrader
NyseDayTrader Jun. 24 at 12:41 PM
$HYFT $HYFT Interesting to see some of the early conversations coming out of BIO. The discussion isn't "Who has the biggest AI model?" It's becoming: Who has the best biological context? One comment asked whether pharma would eventually move away from generic AI models and toward biology-specific architectures. The response: "It's already happening 😊" Maybe that's why we're hearing more about ReefIQ, LensAI, biological context, recurring enterprise contracts, and real-world validation. The market may still be trying to figure out what MindWalk is. The people having these conversations don't seem nearly as confused.
0 · Reply
NyseDayTrader
NyseDayTrader Jun. 24 at 11:03 AM
$HYFT TenGildong🏴‍☠️ @Ten_Gildong Translated from Korean $HYFT Mindwalk technology introduction post에 의견을 남긴 디지털헬스 전략가인 Kat Usop Ricardo, this is a complete game changer in the TechBio field! I'm truly proud to see you breaking down these massive milestones one by one. The approach of anchoring computational reasoning to evolutionary biology, rather than relying on mere standard statistical correlations, is an absolutely brilliant way to tackle the hallucination issues in novel drug development. Moreover, the fact that this approach has already produced validated results in a preclinical dengue program demonstrates that your investment/technology thesis is spot on. Now that the platform has successfully secured its first recurring revenue enterprise contract, do you think this shift to an 'evolution-based' approach will ultimately pressure incumbent big pharma companies to abandon general-purpose foundation models and adopt biology-specific architectures?
0 · Reply
RussMe
RussMe Jun. 24 at 1:47 AM
0 · Reply
Uncle_Salty
Uncle_Salty Jun. 23 at 3:19 PM
$HYFT The endless waiting is
0 · Reply
Tester87100
Tester87100 Jun. 23 at 1:47 PM
0 · Reply
StockingGecks
StockingGecks Jun. 23 at 1:47 AM
0 · Reply
Bigcountry8
Bigcountry8 Jun. 22 at 11:23 PM
$HYFT https://www.foxnews.com/opinion/robert-f-kennedy-jr-future-medicine-built-america
0 · Reply
chucky1110
chucky1110 Jun. 22 at 5:44 PM
$HYFT Bubbles ain't like Keir Starmer - she won't resign willingly! AGM voting is approaching fast! What are you all going to do? Remember, that not bothering to vote = automatic vote for Bubbles! She knows that and that's how she stays in power. I did my research on Ai!
1 · Reply
Right80
Right80 Jun. 22 at 3:50 PM
$HYFT These guys just can't get into the conversation. 10% of the ABSI and ABCL volumes, talking about Dengue for over a year. Let's go already!!
0 · Reply
WenABVEAudit
WenABVEAudit Jun. 22 at 2:27 PM
$HYFT what a turd company and stock
0 · Reply
Wendysnow11
Wendysnow11 Jun. 22 at 1:47 PM
0 · Reply
TradeWhizkid1004
TradeWhizkid1004 Jun. 22 at 1:47 AM
0 · Reply
Mother_Nature
Mother_Nature Jun. 21 at 1:47 PM
0 · Reply
StocksPlusStuffers
StocksPlusStuffers Jun. 21 at 1:47 AM
0 · Reply
CanslerPro
CanslerPro Jun. 20 at 1:47 PM
0 · Reply
Tech4lyfe
Tech4lyfe Jun. 20 at 1:47 AM
0 · Reply
Plan2TradeTrade2Plan
Plan2TradeTrade2Plan Jun. 19 at 8:56 PM
$HYFT best trading day of the week for HYFT!
0 · Reply
IndecisiveTrader
IndecisiveTrader Jun. 19 at 1:47 PM
0 · Reply
Clarkston
Clarkston Jun. 19 at 1:47 AM
0 · Reply
MOMOdough
MOMOdough Jun. 19 at 12:45 AM
$HYFT the acquired a company that was over a decade in the making in development of the AI for 25mil 4 years ago. That was a lot of the heavy lifting R&D expense already completed as it was a smaller shop. The principals of that co have a major stake in the company and sit on the board. In addition the have CRO revenue in the 25mil range per year which at a strong GP provides great profit to cover further expenses. AMD has contributed a major portion of the computing power on AMD’s dime as the feel this is the way of future drug and vaccine discovery. I keep expecting it any day to be caught on to and become a 250mil market cap and never look back.
0 · Reply
gangofone
gangofone Jun. 18 at 11:14 PM
$HYFT I'm new to this ticker. The company's R&D expenses seem thin relative to other expense categories considering what this company does. Can anybody provide insight regarding this?
1 · Reply